

Fimarge International Equity Fund

December 2023

Investment policy

The Sub-Fund will invest up to 100% of its assets in a selected portfolio of international equities (mainly in mid and big capitalizations) traded on organized markets with no geographical constraints. The Sub-Fund may further invest indirectly through other UCITs, including ETFs. Investments in emerging countries will not exceed 30 % of the net assets of the Sub-Fund. The implementation of financial derivatives will only respond to a discretional hedging of currency risk.

Monthly comment

Despite concerns over inflation and rising interest rates, an unexpected regional banking crisis and rising geopolitical tensions around the world, the economies remained resilient and corporate profits were on the rise, leading most major asset classes to deliver strong returns during the final quarter, and reversing the 3Q narrative. Only commodities delivered losses. Returns for the full year were dominated by the 'magnificent seven' tech and Al stocks, which contributed around 80% of the index returns. However, European equities also delivered strong returns. Tightening spreads helped credit, up to a point boosted by the focus on future rate cuts, with falling inflation and dovish messages from major central banks, leading US HY to set as the top fixed income performer. All in all, markets during 2023 bounced from recession worries at the start of the year, to resilient growth at the end. Now, market sentiment over 2024 begins pricing around a soft-landing.


General information	
NAV	102.89
ISIN	LU2474268096
Currency	EUR
Inception date	20/05/2022
Minimum	100 EUR
Fund structure	UCITS V FCP Luxemburgo
Morningstar	Global RV Big Cap Blend
Bloomberg	FIFIEAE:LX
AUMs	€21.1m
Liquidity	Daily

Fees - Class A

1,75%	
No	
No	
0%	
	No No

Monthly performance

	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Year
 2022					4,1%	-6,5%	11,2%	-8,6%	-8,9%	2,1%	6,9%	-3,9%	-5,5%
2023	7.5%	0.9%	-1.3%	0.3%	-0,7%	2.3%	1.7%	-3.8%	-3.9%	-8.0%	10.2%	4.8%	8.9%





Statistics	Accumulated	Annualized	Volatility	Positive months	Max. Drawdown
Fimarge	2,9%	1,7%	20,9%	55,0%	-17,6%
Benchmark	7,7%	4,6%	16,2%	50,0%	-11,7%

Other Information

Manager	Fimarge SFI	Auditor	KPMG
ManCo	NS Partners Europe S.A	Regulator	CSSF
Custodian	Quintet Private Bankers	Platforms	Allfunds Bank, Inversis, Fundsettle


Administrator European Fund Administration (EFA)

Benchmark: (70% STOXX 600) + (30% S&P 500 (€))

Fimarge International Equity Fund

December 2023

Fixed Income 11% Cash 13% Equities 76%



Others 6% Spain 18% Sweden 15% Switzerland 4% Germany 7%


France 7%

Seciol Allocation	
Finance 8%	Pharma 32%
ІТ 16%	Others 13%
	Staples 2%
Industrial 10%	Cyclical 19%

Sector Allocation

Main positions	Weight
Howden Joinery Group PLC	4,2%
Cellavision AB	3,9%
Dermapharm Holding SE	3,8%
Grifols Class B	3,8%
TransMedics Group Inc	3,8%
Alphabet Inc Class C	3,7%
Allfunds Group Plc	3,5%
Inditex	3,4%
PayPal Holdings Inc	3,4%
Sonova Holding AG	3,4%
Top - 10	37,0%

UK 12%



Fimarge, Societat Financera d'Inversió, S.A. Bonaventura Armengol 10, Bloc 1, Pl. 5 AD500 Andorra la Vella – Principat d'Andorra

+376 805 100 - www.fimarge.com fimarge@fimarge.com © Copyright 2018

The information and any estimates, opinions, forecasts and recommendations contained in this document have been prepared by Fimarge and are provided as is; they do not constitute an offer to enter into an agreement. All the valuations and estimates given herein have been prepared by the Portfolio Management Department the date of issue of this report and may be changed without notice. Investors should bear in mind that past performance is not an indication of future performance. The evolution of the benchmark is presented for informational purposes only, although it does not determine management decisions. Fimarge assumes no responsibility for any direct or indirect loss arising from information contained in this document. The information contained herein has been obtained from reliable sources and, although it has been subjected to rigorous review, may contain errors due to the uncertainty of the future performance of the securities analysed or managed. Investors who access this report should bear in mind that the securities or instruments referred to herein may not be appropriate to their investment goals. This report should not be relied on for investment decisions and does not constitute an offer to sell, buy, subscribe for or trade in securities or other instruments.